# iCardiac Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/icardiac-technologies

- Industry: Biotechnology
- Headquarters: Rochester, US
- Website: www.icardiac.com
- Total disclosed funding: $15M
- Latest round: Series B (Oct 15, 2007)
- Investors on record: 4

## About

iCardiac Technologies, Inc. specializes in cardiac safety assessments and data management for clinical trials, focusing on high-quality ECG analysis to support drug development processes.Founded in 2006 in Rochester, US, iCardiac Technologies, Inc. provides cardiac safety assessments utilizing advanced ECG analysis for clinical trials. The company has undergone changes in business strategy to enhance its service offerings. It was acquired by ERT Clinical in December 2017, with terms of the sale undisclosed. The founder's history is not detailed in available resources. iCardiac has completed a total of 5 deals, with its latest funding round being a Series B, which raised USD 6.00 mn from investors including Advantage Capital Partners, Stonehenge Growth Capital, and Trillium Group, totaling USD 6.00 mn raised to date.iCardiac Technologies, Inc. provides specialized cardiac safety assessments and ECG data management services for the pharmaceutical industry. Their offerings include comprehensive ECG analysis, reporting, and data management solutions tailored to meet the needs of clinical trials, ensuring regulatory compliance and data integrity. The company serves clients globally, focusing on pharmaceutical and biotechnology sectors, facilitating their drug development processes with precise cardiac safety evaluations.iCardiac Technologies, Inc. generates revenue through a service-based model that offers cardiac safety assessments and ECG analysis for clinical trials. The revenue is derived from contracts with pharmaceutical and biotech companies that require rigorous cardiac evaluation services as part of their drug development pipeline. Each service is structured to meet specific project needs, ensuring clients receive tailored solutions.With the funding raised in December 2017, iCardiac Technologies, Inc. aims to enhance its service portfolio and expand its market reach. The company plans to introduce new ECG analysis technologies to improve data accuracy and efficiency. Additionally, iCardiac is targeting growth into European and Asian markets by 2025, leveraging its acquisition by ERT Clinical to integrate its services into broader clinical trial solutions, thereby strengthening its competitive position in the industry.

## Funding rounds

- Series B, Oct 15, 2007, $6M — Advantage Capital, Trillium Group, Stonehenge Growth Capital
- Series A, Jan 30, 2007, $5M — Pfizer Venture Investments
- Series A, Nov 7, 2006, $4M — Advantage Capital, Trillium Group, Stonehenge Growth Capital

## Investors

- Advantage Capital — Series A, Series B
- Trillium Group (https://capitalatlas.ai/funds/trillium-group) — Series A, Series B
- Stonehenge Growth Capital (https://capitalatlas.ai/funds/stonehenge-growth-capital) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A